GlassScriptPhysician profile
James R Campbell
NPI 1720091077
$35,052.59
in general payments reported to CMS, 2019-2025
69 companies · $5,884 in 2025
The $5,884 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,045 · 2020: $3,279 · 2021: $5,035 · 2022: $4,927 · 2023: $5,465 · 2024: $5,417 · 2025: $5,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,612.49 |
| Education | $153.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,626.43 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $2,845.41 | 2021-2025 | Vraylar, Ubrelvy, Botox |
| Amgen INC. | $1,904.30 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $1,696.50 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $1,626.26 | 2021-2025 | |
| Novo Nordisk INC | $1,576.51 | 2019-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,384.67 | 2019-2025 | Jardiance |
| Pfizer INC. | $1,298.22 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,265.70 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $1,249.78 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Vanda Pharmaceuticals INC. | $1,005.95 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $995.77 | 2019-2025 | Austedo Xr, Austedo Xr |
| Amarin Pharma, INC. | $841.41 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $811.44 | 2019-2023 | Verquvo, Belsomra |
| Corium, LLC | $753.45 | 2023-2025 | Azstarys, Azstarys |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $563.65 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $562.31 | 2019-2023 | |
| Antares Pharma, INC. | $538.93 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Noven Therapeutics, LLC | $537.58 | 2023-2025 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $532.54 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $525.40 | 2022-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $521.97 | 2019-2025 | Xifaxan |
| Allergan, INC. | $521.40 | 2019-2022 | |
| Abbott Laboratories | $510.77 | 2021-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $462.17 | 2022 | |
| Astellas Pharma US INC | $457.52 | 2019-2025 | Veozah |
| Intra-Sana Laboratories | $454.84 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Boston Scientific Corporation | $397.66 | 2024-2025 | Cds Broad Portfolio Offering, Bodyguardian |
| Kowa Pharmaceuticals America, INC. | $365.07 | 2019-2024 | Livalo, Seglentis |
| Arbor Pharmaceuticals, INC. | $328.77 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $327.26 | 2019 | |
| Azurity Pharmaceuticals, INC. | $281.93 | 2023-2025 | Edarbi, Horizant |
| Daiichi Sankyo INC. | $277.70 | 2020-2021 | |
| Mannkind Corporation | $264.73 | 2022-2025 | |
| Abiomed | $235.70 | 2024 | Impella |
| Kyowa Kirin, INC. | $231.98 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $224.97 | 2021 | |
| Phathom Pharmaceuticals, INC. | $218.16 | 2024-2025 | Voquezna |
| Dexcom, INC. | $213.91 | 2024-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Alk-Abello, INC | $205.27 | 2024 | Ragwitek, Odactra, Grastek |
| Clarus Therapeutics INC. | $191.60 | 2021 | |
| Exact Sciences Corporation | $191.00 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $175.65 | 2023-2024 | Quviviq |
| Almatica Pharma LLC | $167.36 | 2022-2025 | Loreev Xr |
| Sanofi-Aventis U.S. LLC | $154.93 | 2020-2023 | |
| Jazz Pharmaceuticals INC. | $146.81 | 2021 | |
| Galderma Laboratories, L.P. | $126.24 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $125.65 | 2022-2023 | Xyosted, Qelbree |
| Biohaven Pharmaceuticals, INC. | $125.31 | 2021 | |
| Indivior INC. | $124.34 | 2020 | |
| Esperion Therapeutics, INC. | $124.34 | 2021 | |
| Noven Pharmaceuticals, INC. | $111.16 | 2024 | Xelstrym |
| Pulmonx Corporation | $110.43 | 2023 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Sumitomo Pharma America, INC. | $108.61 | 2023-2025 | Gemtesa |
| Biogen, INC. | $65.55 | 2021 | |
| Horizon Therapeutics Plc | $60.57 | 2021-2022 | |
| Halozyme INC | $52.78 | 2023 | |
| Eisai INC. | $52.52 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $29.33 | 2025 | Relexxii |
| Revance Therapeutics, INC. | $25.14 | 2025 | Daxxify |
| Nevro Corp. | $21.53 | 2022 | |
| Paratek Pharmaceuticals, INC. | $21.26 | 2025 | Nuzyra |
| Viatris Specialty LLC | $17.43 | 2025 | Yupelri |
| Lundbeck LLC | $16.63 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $15.24 | 2019 | |
| Acella Pharmaceuticals, LLC | $12.84 | 2022 | |
| Therapeuticsmd, INC. | $12.14 | 2022 | |
| Adlon Therapeutics L.P. | $11.25 | 2019 | |
| Merz North America, INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.